FindTrial
Sign In

Research on combination therapy in neovascular glaucoma

Efficacy of conbercept combined with vitrectomy and endocyclophotocoagulation in neovascular glaucoma with corneal edema

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071003
Enrollment
Unknown
Registered
2023-04-28
Start date
2019-09-07
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular glaucoma

Interventions

A (consecutive 3 conbercept injections comined with vitrectomy and endocyclophotocoagulation):None
B (a single conbercept injection comined with vitrectomy and endocyclophotocoagulation):None

Sponsors

Taiyuan Aier Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
33 Years to 77 Years

Inclusion criteria

Inclusion criteria: 1) age = 18 years; 2) IOP > 21mmHg after conbercept intravitreal injection and anti-glaucoma medications (at least 3 kinds); 3) medium was unclear (including corneal edema, cataract and vitreous hemorrhage (VH)/tractional retinal detachment).

Exclusion criteria

Exclusion criteria: 1) had a previous history of vitreoretinal surgery and intravitreal anti-VEGF and history of ocular surgery within the previous 6?months; 3) BCVA with no light perception before surgery; 4) follow-up period of <12?months.

Design outcomes

Primary

MeasureTime frame
IOP;—

Secondary

MeasureTime frame
BCVA;NVI;—

Countries

China

Contacts

Public ContactJian Jiang

Taiyuan Aier Eye Hospital

thisisjiangjian@126.com+86 18561815807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026